For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Global Blood Therapeutics, Inc.

USPTO Granted Patents = 57

CIPO Patents = 26

EPO Patents = 23

Trademarks = 17

Forward Citations = 793

Loading Chart...

Loading Chart...

82 inventors (with patents filed for the assignee):

Zhe Li (42 out of 54 patents)

Qing Xu (24 out of 53 patents)

Brian Walter Metcalf (22 out of 87 patents)

4. Calvin Wesley Yee (13 out of 15 patents)

5. Stephen L Gwaltney, Ii (10 out of 10 patents)

6. Ming Yu (10 out of 30 patents)

7. Jason R Harris (10 out of 10 patents)

8. Chihyuan Chuang (8 out of 36 patents)

9. Travis Lee Houston (6 out of 24 patents)

10. Stephan D Parent (6 out of 49 patents)

11. Lina Quattrocchio Setti (6 out of 11 patents)

12. Manuel Zancanella (5 out of 9 patents)

13. Hing L Sham (5 out of 92 patents)

14. Chul Yu (4 out of 4 patents)

15. Peter Michael Rademacher (3 out of 3 patents)

Core Competencies:

Hemoglobin Modulators

Ferroportin Inhibitors

Histone Methyltransferase Inhibitors

Cycloalkyl Pyrimidines

Tricyclic Compounds

Pyruvate Kinase Activators

Crystalline Polymorphs

Substituted Heteroaryl Aldehydes

Bicyclic Kallikrein Inhibitors

Azaindole Compounds

Tissue Oxygenation

Dosing Regimens

57 patents: Sort by Forward Citations

1. 12473277 - Solid forms of a modulator of hemoglobin (2025-11-18),

2. 12202817 - Cycloalkyl pyrimidines as ferroportin inhibitors (2025-01-21),

3. 11944612 - Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (2024-04-02),

4. 11939323 - Methods of making a modulator of hemoglobin (2024-03-26),

5. 11851424 - Solid forms of a modulator of hemoglobin (2023-12-26),

6. 11746100 - Cycloalkyl pyrimidines as ferroportin inhibitors (2023-09-05),

7. 11713299 - Histone methyltransferase inhibitors (2023-08-01),

8. 11661410 - Tricyclic compounds as histone methyltransferase inhibitors (2023-05-30),

9. 11584734 - Tricyclic compounds as histone methyltransferase inhibitors (2023-02-21),

10. 11566030 - Substituted 2,6-dihydropyrrolo[3,4-c]pyrazoles as pyruvate kinase activators (2023-01-31),

11. 11548880 - Modulators of hemoglobin (2023-01-10),

12. 11530191 - Compounds and uses thereof for the modulation of hemoglobin (2022-12-20),

13. 11452720 - Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde (2022-09-27),

14. 11286243 - Ferroportin inhibitors and methods of use (2022-03-29),

15. 11254651 - Histone methyltransferase inhibitors (2022-02-22),

Global Blood Therapeutics, Inc. (GBT) is a biopharmaceutical company dedicated to discovering, developing, and delivering innovative treatments for people with severe blood diseases. GBT's mission is to transform the lives of these patients by developing therapies that address the underlying genetic causes of their conditions. With a focus on sickle cell disease, GBT is committed to improving the treatment landscape and bringing hope to millions of patients around the world.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

57 Patents

#23 in South San Francisco, CA

#1,424 in California

#6,037 in US

#12,152 in the World

South San Francisco, CA, United States of America

Global Blood Therapeutics, Inc.

Forward Citations = 793

82 inventors:

Zhe Li (42 out of 54 patents)

Qing Xu (24 out of 53 patents)

Brian Walter Metcalf (22 out of 87 patents)

4. Calvin Wesley Yee (13 out of 15 patents)

5. Stephen L Gwaltney, Ii (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…